1 February 2019 - The cell-free fetal DNA (cffDNA) test is a new
technology being used to assess the risk of a pregnant woman’s developing baby
(fetus) against any abnormalities such as chromosome disorder like Down sydrome
(trisomy 21), Edwards syndrome (trisomy 18) or Patau syndrome (trisomy 13). The
global cell-free fetal DNA testing market is segmented on the basis of test
types and geography. This new technology is being used as an alternative to
currently available prenatal tests. It may be used to identify other rare
conditions resulting from an extra chromosome or missing piece of chromosome
(microdeletion).
This
new prenatal disorder testing technology is expected to be driven by major
factors such as safe and low risk obstetric nature of this technology for
prenatal testing coupled with increasing awareness about inherited disorders.
The two predominant prenatal tests are chorionic villus sampling (CVS) and
amniocentesis, both are invasive and could possess harm to the developing
fetus, in some cases it can cause miscarriage. Cell-free fetal DNA is a new
alternative of prenatal tests.
Fetal
DNA is found in mother’s blood stream, cell-free fetal DNA enters into the
blood stream through the placenta, placenta is a flattened organ in the uterus
where maternal blood and fetal blood. The fetal DNA can be split into very
acute fragments, less than 200 base pairs on an average. Maternal DNA fragments
are also present in the blood.
Fetal
DNA is first noticed after 22-25 days of fertilization and its concentrations
increase as the time period of pregnancy increases. Diagnostic tests for
pregnancy using fetal DNA is possible in seventh week of pregnancy. Fetal DNA
can be rarely distinguished from the maternal DNA through diagnostic practice.
Amniocentesis
and chorionic villus sampling prenatal test is possible within 14-20 weeks and
10-13 weeks of pregnancy respectively. Cell-free fetal DNA non-invasive test is
used to detect aneuploidy syndromes, fetal Down syndrome and signals a major
shift in diagnostic practice and prenatal screening.
The
primary factor for the growth of global cell-free fetal DNA testing industry is
growing awareness in the people and requirement of safe or low risk obstetric
procedures for prenatal testing. The technology which is used in cell-free DNA
analysis and its application to prenatal screening for aneuploidy is rapidly
changing. The growth of cell-free fetal DNA testing market is primarily
attributed to accurate and effective results for aneuploidy screening. Major factor
which limits the growth of the global cell-free fetal DNA testing market is
high cost of cell-free fetal DNA tests.
The
cell-free fetal DNA testing enables the parents to get information about
general survivable fetal aneuploidies with a high accuracy and without any
diagnostic procedure risk. In comparison with other screening method of
aneuploidy, cell-free fetal DNA testing offers various advantages such as lower
false-positive results of cell-free fetal DNA test as compared to other
screening method.
Aneuploidy
is an unusual number of chromosomes, typically characterized by the absence of
one copy of a single chromosome or by the increase in the amount of
chromosomes. The presence of an extra copy of chromosome 21 is called trisomy
21, which causes Down syndrome. On the basis of test types, the global
cell-free fetal DNA testing industry is segmented into detection of abnormal
chromosome number, paternally inherited disorders, gender testing and so on.
On
the basis of geography, the global cell-free fetal DNA testing market is
segmented into North America, Europe, Asia Pacific, Japan, Latin America and
Middle East & Africa. North America held largest share in the global market
of cell-free fetal DNA testing followed by Europe, Japan and Asia Pacific owing
to high occurrence of several diseases and increasing number of aneuploidies,
great advancement in field of aneuploidy screening and developed healthcare
infrastructure. The developing nations in Asia Pacific, Middle East and Africa
hold huge potential for growth in the global cell-free fetal DNA testing
market, due to its quick and accurate result without any risk to developing
fetus.
The
key players of global cell-free fetal DNA testing market are IIIumina Inc.,
Sequenom Laboratories, Ariosa Diagnostics, Arup Laboratories, The Fetal
Medicine Centre, Apollo Path Labs, Agilent Technology, Biodesix Inc., Allenex
AB, Biocept Inc., CareD Inc., Guardant Health Inc., Inivated Limited, Natera
Inc., Quest Diagnostics, Roche Holdings AG, Sequenom Inc. and Trovagene Inc.
Market Segment:
This report studies the global Cell-Free
Fetal DNA Testing market, analyzes and researches the Cell-Free Fetal DNA
Testing development status and forecast in United States, EU, Japan, China,
India and Southeast Asia. This report focuses on the top players in global
market, like
•
Sequenom Laboratories
•
Illumina, Inc.
•
Ariosa Diagnostics
•
Arup Laboratories
•
The Fetal Medicine Centre
•
Apollo Path labs
Market segment by Regions/Countries,
this report covers
•
United States
•
EU
•
Japan
•
China
•
India
•
Southeast Asia
Comments
Post a Comment